Escalent Acquires C Space, Hall & Partners

Union gives rise to an impressive global partner to the world’s leading businesses

Melissa Sauter

Escalent CEO

DETROIT, April 12, 2023 (GLOBE NEWSWIRE) — Top data analytics and advisory firm Escalent announces today it has acquired C Space and Hall & Partners from Omnicom. As leading partners to some of the world’s exceptional brands, Escalent, C Space and Hall & Partners have been helping companies innovate, improve, and navigate disruption for years. Now they are coming together to create a bigger, stronger and more capable partner to the world’s leading companies, combining deep industry expertise across brands, customers and products on a focused, global market insights platform to help clients find new sources of growth.

Together, the organizations have earned trusted partner status to the world’s leading brands across fast-growing industries including Automotive & Mobility, Consumer Goods & Retail, Financial Services, Health, and Technology as well as Energy, Telecom and Travel & Tourism.

“This union is rooted in unparalleled expertise in what drives human beings, cultures and markets—an understanding that makes our team incredibly valuable partners and positions our clients for success in today’s fast-paced, ever-changing business climate,” said Escalent CEO Melissa Sauter. “Together, there is tremendous growth potential for our employees, clients and shareholders across the globe.”

Escalent + C Space, Hall & Partners

Escalent Acquires C Space, Hall & Partners

Hall & Partners brings an excellent research and brand management franchise coupled with proprietary technology including an award-winning brand knowledge management platform to the union. C Space brings the market-leading solution for building communities and customer relationships, and Escalent brings a strong global platform with deep industry knowledge, and advanced capabilities in secondary research and analytics. The combined organization creates a powerful global presence with nearly 2,000 consultants, researchers, data scientists, technologists and operational experts in 20 countries.

“This acquisition is a big win for our employees,” added C Space CEO Jessica DeVlieger. “Our organizations are forward-thinking and offer employees an opportunity to nurture their professional growth through expanded products and services that have a real impact on our clients, in an environment that celebrates diversity and recognizes each team member’s valuable contributions.”

“Over the coming year, cross-company teams will work together to develop a thoughtful plan that ensures our clients and employees feel the benefits from our combined organization,” said Hall & Partners CEO Tim Wragg. “We are perfectly balanced to offer deep resources and leading technology while remaining devoted to personal client relationships. We’re eager to start working toward our future.”

DeVlieger and Wragg will continue to lead their organizations as part of Sauter’s executive leadership team. Clients will continue to work with the same experienced teams, and there are no near-term plans to change company locations or merge brand identities.

“We are very excited to put together these amazing capabilities into a focused, yet global leader dedicated to the highest quality research and insights for our clients. Together the companies create a fantastic combination of depth of expertise with scale and growth capability, while still being focused on one shared core mission. As such, the combined organization will continue to differentiate with their clients through exceptional insights and partnership,” said J.T. Treadwell, Managing Director at STG, Escalent’s financial sponsor.

About Escalent
Escalent is an award-winning data analytics and advisory firm specializing in industries facing disruption and business transformation. As catalysts of progress for more than 40 years, we accelerate growth by creating a seamless flow between primary, secondary, syndicated, and internal business data, providing consulting and advisory services from insights through implementation. Escalent is headquartered in Livonia, Michigan with locations across the US and in Canada, China, India, Ireland, the Philippines, Singapore, South Africa, UAE and the UK. Visit escalent.co to see how we are helping shape the brands that are reshaping the world.

About C Space

C Space is a global customer insight, strategy and innovation agency building customers into the ways businesses work. Partnering with the world’s best-known brands including Walmart, McDonald’s, IKEA and more, C Space helps clients unlock growth through the power of human relationships—co-creating with customers, instead of for them, for increased relevance, deeper loyalty and higher customer lifetime value. C Space’s full-service customer solutions are tailored to meet specific business needs with a focus on private online communities, co-creation events, workshops and powerful storytelling and insights activation. Headquartered in Boston, C Space has offices in London, New York, San Francisco and Mexico City.

About Hall & Partners

Hall & Partners is a team of unconventional thinkers, obsessed with how marketing influences the relationship between people, brands and culture. Born out of adland, we are the insight agency known for weaving creativity with science. We distil data through a strategic lens to reveal ‘uncommon insights’ – human truths tailored to individual brands, not blackbox data available to the masses. We partner with clients to shape brand strategy and optimize brand and campaign performance. Our award-winning approach amplifies insights across every business area, propelling marketing decision-making to create an unmatched competitive advantage. Headquartered in London, Hall & Partners has offices in New York, Los Angeles, and Chicago.

Photos accompanying this announcement are available at:

https://www.globenewswire.com/NewsRoom/AttachmentNg/a9fa10fe-a141-4ab5-9823-af7a6ccf35c3

https://www.globenewswire.com/NewsRoom/AttachmentNg/fd85618f-f66f-4b47-957b-53e9fb689ffb

Contact        
Lisa Viselli, 734.779.6851

lisa.viselli@escalent.co

GlobeNewswire Distribution ID 8806130

Colliers acquires New Zealand’s leading project manager

Adds scale and strengthens capabilities in region

TORONTO and AUCKLAND, New Zealand, April 12, 2023 (GLOBE NEWSWIRE) — Global diversified professional services and investment management company Colliers (NASDAQ, TSX: CIGI) announced today it has acquired a controlling interest in Greenstone Group Ltd. (“Greenstone”), a leading project management and property advisory firm in New Zealand. The Greenstone senior leadership team will remain significant shareholders of the business under Colliers’ unique partnership model. The business will rebrand as “Colliers Project Leaders” and integrate into Colliers’ market-leading New Zealand operations. Terms of the transaction were not disclosed.

Founded in 2000, Greenstone offers project management and property advisory services to a diverse range of end-markets including commercial and residential developers, as well as the government, education, and infrastructure sectors. Greenstone’s professional services are delivered by more than 55 professionals across four offices in New Zealand.

“Our partnership with Greenstone builds on several successful investments that we have made in our Colliers Engineering & Design and Colliers Project Leaders businesses, highlighting our focus on building high-value, resilient and recurring professional services businesses that can leverage our global brand and footprint,” said Elias Mulamoottil, Co-Chief Investment Officer of Colliers. “Our differentiated approach continues to attract leading firms that value our unique partnership model, long-term growth horizon, and decentralized and enterprising culture.”

“The addition of Greenstone will strengthen our overall Colliers Project Leaders offering, allowing us to support our clients across the region with their more complex challenges,” said John Kenny, CEO Colliers Asia Pacific. “From our first meeting, we knew that Greenstone shared our enterprising values and culture, and we are excited to welcome these trusted professionals into the Colliers organization.”

“By joining with a partner that shares our passion, values and focus on service excellence, we can focus on the future of our business,” said Shane Davis, Managing Director of Greenstone. “We look forward to leveraging the Colliers brand, global platform, and client relationships to help accelerate the success of our shared clients and professionals in the years to come.”

About Colliers

Colliers (NASDAQ, TSX: CIGI) is a leading diversified professional services and investment management company. With operations in 65 countries, our 18,000 enterprising professionals work collaboratively to provide expert real estate and investment advice to clients. For more than 28 years, our experienced leadership with significant inside ownership has delivered compound annual investment returns of approximately 20% for shareholders. With annual revenues of $4.5 billion and $98 billion of assets under management, Colliers maximizes the potential of property and real assets to accelerate the success of our clients, our investors and our people. Learn more at corporate.colliers.com, Twitter @Colliers or LinkedIn.

Contacts

John Kenny
Chief Executive Officer | Asia Pacific
+61 2 9257 0222

Elias Mulamoottil
Co-Chief Investment Officer | Global
(416) 960-9500

GlobeNewswire Distribution ID 8806208

Nasdaq Enhances Risk Platform to Help Banking and Broker-Dealer Community Manage Real-Time Risk

Significant upgrades incorporating additional asset classes and live streaming capability to better navigate extreme market volatility

Number of customers using the Nasdaq Risk Platform increased by over 50% in the last 12 months, reflecting substantial increase in demand for real-time risk capability

NEW YORK, April 12, 2023 (GLOBE NEWSWIRE) — Nasdaq (Nasdaq: NDAQ) today announced it has made a series of enhancements to its risk technology platform, which is widely used by the banking and broker-dealer community to manage liquidity and market risk. The upgrades will help firms better navigate extreme market conditions, providing a live view of risk across proprietary and client trading portfolios with detailed analytics to support real-time decision-making.

The latest major release of the Nasdaq Risk Platform adds fixed income securities including Government Bonds, Corporate Bonds and Convertible Bonds to offer users a consolidated view of risk across a broad range of asset classes including Fixed Income, Equities and Equity Options, Exchange Traded Derivatives and Foreign Exchange. It also significantly enhances multi-factor and intraday stress testing tools that are capable of isolating and managing specific risks within large and complex scenario sets.

“The extreme volatility in recent weeks has demonstrated the consequences of firms not understanding their intra-day liquidity and market risk. We’ve seen a significant increase in demand from banks and broker-dealers who recognize the importance of being able to distill, analyze, interpret, and act on signals in a genuinely live environment,” said Roland Chai, Executive Vice President and Head of Marketplace Technology at Nasdaq. “Our position as both a technology and markets infrastructure provider means that we are uniquely placed to help firms navigate these unprecedented headwinds.”

Other significant enhancements include adding an open source distributed streaming system, Kafka, to feed live risk analytics, and fully incorporating Nasdaq Derivatives Pricing into the platform. Delivered via the Nasdaq Risk Platform or standalone, Nasdaq Derivatives Pricing provides streaming option analytics including theoretical prices, greeks and recalibrated option volatilities to clients. The integration enables firms to conduct P&L, Value at Risk (VaR) and stress testing calculations on option portfolios which is done using recalibrated intraday volatility surfaces, a three-dimensional plot mapping option values against the possible strike prices of an underlying stock.

The platform is a key growth area for of Nasdaq’s Marketplace Technology business, with the company increasing its customer base by 50% over the last 12 months.

Timely Capabilities to Navigate a Volatile Environment

Magnus Haglind, Senior Vice President and Head of Products for Marketplace Technology at Nasdaq said: “Many firms still rely on receiving end-of-day pricing and margin calls, leaving them exposed to significant intraday volatility and the risk of a liquidity crunch. This threat is only going to increase as we move into a higher interest rate environment with even greater risk embedded in bond and derivative portfolios. Nasdaq Risk Platform provides firms with a consolidated and real-time view of risk across asset-classes, exchanges and CCPs and brings wider benefits in the form of more efficient collateral management, which can help unlock liquidity and boost returns.”

Built in the cloud, and deployed via SaaS, the platform has the ability to scale rapidly at times of high market volatility. It is developed and maintained by Nasdaq, applying the same high standards and levels of monitoring and support the company applies to its own marketplaces.

About Nasdaq
Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software, and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on LinkedIn, on Twitter @Nasdaq, or at www.nasdaq.com.

Nasdaq Media Contact:
Andrew Hughes
+44 (0)7443 100896
Andrew.Hughes@nasdaq.com

-NDAQG-

GlobeNewswire Distribution ID 8805867

GlobeNewswire เครือข่ายการเผยแพร่และแจกจ่ายข่าวของ Notified ได้เผยแพร่ข่าวประชาสัมพันธ์จำนวนมากเป็นประวัติการณ์ในปี 2022 ส่งผลให้มีการเผยแพร่ข่าวเพิ่มขึ้น 16% ในช่วงสองปีที่ผ่านมา

Notified ห็นแรงผลักดันที่มีอย่างต่อเนื่องและให้แนวทางปฏิบัติที่ดีที่สุดสำหรับการเผยแพร่ข่าวประชาสัมพันธ์

นิวยอร์ก 11 เมษายน, April 12, 2023 (GLOBE NEWSWIRE) — Notified พันธมิตรด้านเทคโนโลยีที่ได้รับความไว้วางใจจากทั่วโลกในการเป็นผู้เชี่ยวชาญด้านการประชาสัมพันธ์ นักลงทุนสัมพันธ์ และการตลาดได้ประกาศในวันนี้ว่า GlobeNewswire ได้เห็นการเพิ่มขึ้น 16% ในเรื่องของข่าวประชาสัมพันธ์ที่เผยแพร่โดยลูกค้าในช่วงสองปีที่ผ่านมา การเติบโตนี้ได้รับการตอกย้ำโดยผลการศึกษาล่าสุด ซึ่งดำเนินการโดยความร่วมมือกับ PRWeek โดยพบว่า 79% ของผู้เชี่ยวชาญด้านการประชาสัมพันธ์เชื่อว่าข่าวประชาสัมพันธ์เป็นส่วนสำคัญของสื่อผสม โดย 65% รายงานว่ากลุ่มผู้เชี่ยวชาญดังกล่าวได้ทำงานเกี่ยวกับเนื้อหาที่เผยแพร่ ‘อย่างเป็นวงกว้าง’

GlobeNewswire เป็นหนึ่งในเครือข่ายการกระจายข่าวที่ใหญ่ที่สุดในโลก ซึ่งรับผิดชอบในการนำเสนอการสื่อสารที่สำคัญต่อภารกิจอย่างปลอดภัยและเชื่อถือได้ในนามของบริษัทต่าง ๆ ที่ใหญ่ที่สุดในโลก 2,000 อันดับแรกเป็นจำนวนกว่าหนึ่งในสาม โดยได้เผยแพร่ข่าวประชาสัมพันธ์มากกว่า 150 ประเทศและ 35 ภาษาเพื่อผลักดันการมองเห็นให้กับข่าวและประกาศสำคัญของบริษัท เครือข่ายนี้ได้รับการยกย่องจากลูกค้าอย่างต่อเนื่องในด้านการให้การสนับสนุนคุณภาพสูง และได้รับป้ายยกย่องห้าป้ายใน G2 Spring Report 2023 เนื่องจากได้รับคะแนนสูงจากผู้ใช้ปัจจุบัน

ในปีที่แล้ว GlobeNewswire จึงได้เพิ่มวงจรสิ่งแวดล้อม สังคม และธรรมาภิบาล (ESG) ใหม่สามวงจร ซึ่งครอบคลุมอเมริกาเหนือ ยุโรป และภูมิภาคเอเชียแปซิฟิกเพื่อตอบสนองความต้องการที่เปลี่ยนแปลงไปของธุรกิจทั่วโลก แต่ละวงจรประกอบด้วยเครือข่ายการเผยแพร่ระดับภูมิภาคที่ครอบคลุม บวกกับรายชื่อนักข่าวที่มีความสนใจเป็นพิเศษใน ESG และความรับผิดชอบต่อสังคมขององค์กรซึ่งได้รับการคัดสรรมาอย่างดี ตลอดจนการค้าที่ครอบคลุมหัวข้อด้านสิ่งแวดล้อมและการกุศล

ในปีนี้ GlobeNewswire ได้มุ่งเน้นในด้านการพัฒนาเทคโนโลยีการประชาสัมพันธ์ โดยทำงานร่วมกันกับผู้ที่จะใช้เทคโนโลยีนี้ เมื่อเดือนที่แล้ว บริษัทได้เปิดตัวเครื่องมือ AI ตัวแรกสำหรับการสร้างสิ่งต่าง ๆ ขึ้นใหม่ เพื่อสร้างข่าวประชาสัมพันธ์ที่นำเสนอโดยบริการแจกจ่ายข่าว หากต้องการเรียนรู้เพิ่มเติมและสมัครโปรแกรมสร้างข่าวประชาสัมพันธ์โดยใช้ AI ของ GlobeNewswire รุ่นเบต้า กรุณาเยี่ยมชม https://insight.notified.com/globenewswire-ai

Jessica Brown รองประธานฝ่ายการตลาดของ Notified กล่าวว่า “การเติบโตอย่างต่อเนื่องของ GlobeNewswire เป็นเครื่องพิสูจน์ว่าข่าวประชาสัมพันธ์ไม่ได้หายไปไหน อันที่จริงแล้ว เครื่องมือสื่อสารนี้เป็นเครื่องมือที่สำคัญอย่างยิ่งในสภาพแวดล้อมทางธุรกิจที่เปลี่ยนแปลงตลอดเวลา เพื่อให้บริษัทต่าง ๆ ได้บอกเล่าเรื่องราวของตน” “สำหรับองค์กรทุกขนาด ข่าวประชาสัมพันธ์เป็นแหล่งความจริงแหล่งเดียวที่ไม่สามารถโต้แย้งได้ และมีความสำคัญต่อกลยุทธ์การสื่อสารขององค์กร ผู้เชี่ยวชาญด้านการประชาสัมพันธ์สามารถรับประโยชน์จากการทำความเข้าใจในแนวทางปฏิบัติที่ดีที่สุดสำหรับการเผยแพร่ข่าวที่มีการปรับปรุงโดยตรงในด้านการมองเห็น การแจกจ่าย และผลลัพธ์ทางสื่อที่ได้รับ”

สามารถดูตัวอย่างข้อมูลสื่อที่มาพร้อมกับประกาศนี้ได้โดยเลือกรูปภาพหรือลิงก์ด้านล่าง:

GlobeNewswire, Notified’s Newswire Distribution Network, Distributed a Record Number of Press Releases in 2022, Resulting in a 16% Increase Over the Last Two Years: Notified Sees Continued Momentum and Provides Best Practices for Press Release Distribution

เคล็ดลับต่อไปนี้ระบุไว้ใน eBook ล่าสุดของ Notified ที่ชื่อว่า “วิธีปรับปรุงการเข้าถึงสื่อของคุณในปี 2023” ซึ่งให้แนวทางสำหรับผู้สื่อสารเพื่อเพิ่มประสิทธิภาพ ROI ให้กับข่าวประชาสัมพันธ์:

  • เข้าใจ SEO: ปรับปรุงการเพิ่มประสิทธิภาพเครื่องมือค้นหาโดยจัดคำหลักให้ตรงกับข้อความและกลุ่มเป้าหมายด้วยวิธีที่เป็นธรรมชาติ โปรดจำไว้ว่าบรรทัดแรกที่นำเสนอในข่าวประชาสัมพันธ์คือสิ่งที่จะมีการดูในผลการค้นหาของ Google
  • คิดเหมือนนักข่าว: เขียนอย่างเป็นกลางและมีชั้นเชิงเพื่อสร้างข่าวประชาสัมพันธ์ที่มีความฉับไวและอ่านง่าย ควรหลีกเลี่ยงศัพท์เฉพาะกลุ่มและอย่าลืมนำด้วยข้อเท็จจริงที่ควรค่าแก่การเป็นข่าว โดยใช้คำพูดและข้อมูลเป็นข้อพิสูจน์
  • ใช้มัลติมีเดียเพื่อปรับปรุงผลลัพธ์: สร้างข่าวประชาสัมพันธ์ที่ครอบคลุมและมีส่วนร่วมมากขึ้นโดยการรวมรูปภาพ วิดีโอ คลิปเสียง กราฟิก และสื่ออื่น ๆ แบบฝัง (และดาวน์โหลดได้) ในข้อความแสดงแทนรูปภาพ ให้เพิ่มคีย์เวิร์ดหรือข้อความค้นหาที่เกี่ยวข้องเพื่อเพิ่มผลลัพธ์การค้นหา ใช้ภาพที่บีบอัดและชื่อนามสกุลไฟล์มาตรฐาน เช่น .jpg หรือ .jpeg และชื่อหัวเรื่องที่สื่อความหมาย
  • ใช้ประโยชน์จากห้องข่าวออนไลน์ของคุณ: ในสภาพแวดล้อมของสื่อที่ท้าทาย ห้องข่าวจะทำหน้าที่เป็นทรัพยากรที่มีเนื้อหาที่ทันสมัย ง่ายต่อการบริโภค และเป็นแหล่งข้อมูลที่นักข่าวและผู้มีส่วนได้ส่วนเสียไว้วางใจ

หากต้องการเรียนรู้เพิ่มเติมเกี่ยวกับ GlobeNewswire กรุณาเยี่ยมชม: https://www.globenewswire.com/

เกี่ยวกับ Notified
Notified มุ่งมั่นที่จะทำให้แบรนด์ต่าง ๆ สามารถสร้างและแบ่งปันเรื่องราวอันทรงพลังกับคนทั้งโลกได้อย่างง่ายดาย ชุดโซลูชันระดับโลกที่ได้รับรางวัลและทีมบริการลูกค้าที่ทุ่มเทของเราได้รับความไว้วางใจจากลูกค้าทั่วโลกมากกว่า 10,000 ราย ตั้งแต่ธุรกิจที่กำลังเติบโตและบริษัทมหาชนไปจนถึงแบรนด์ที่เป็นที่รู้จักมากที่สุดในโลก

โซลูชันของ Notified ช่วยให้ธุรกิจต่างๆ แบ่งปันและขยายเรื่องราวของตนได้อย่างมีประสิทธิภาพแก่ลูกค้า นักลงทุน พนักงาน และสื่อต่าง ๆ Notified มีบริการต่าง ๆให้คุณอย่างครอบคลุม ตั้งแต่การเผยแพร่ข่าวประชาสัมพันธ์ผ่าน GlobeNewswire ไปจนถึงการรับสาย เว็บไซต์ IR การฟังทางสังคม การมีส่วนร่วมกับสื่อ การสัมมนาผ่านเว็บ และประสบการณ์ดิจิทัล Notified เป็นส่วนหนึ่งของ West Technology Group, LLC (เดิมคือ Intrado Corporation) ซึ่งควบคุมโดยบริษัทในเครือของกองทุนบางแห่งที่บริหารโดย Apollo Global Management, Inc. (NYSE: APO). Notified มีสำนักงานใหญ่ในเมืองนิวยอร์ก รัฐนิวยอร์ก

เรียนรู้เพิ่มเติมได้ที่ www.notified.com หรือติดตามเราได้ที่ ลิงกต์อิน ทวิตเตอร์หรือ บล็อกของเรา

ติดต่อ:
Hannah Freedman
ผู้อำนวยการฝ่ายสื่อและการสื่อสาร
hannah.freedman@notified.com

GlobeNewswire Distribution ID 8806317

Junshi Biosciences Announces Phase 3 Clinical Study of Senaparib for Advanced Ovarian Cancer Maintenance Treatment Following First-line Therapy Met Primary Endpoint

SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced that a randomized, double-blind, placebo-controlled, multi-center phase III clinical study (“FLAMES Study”, NCT04169997) investigating the poly (ADP-ribose) polymerase (“PARP”) inhibitor, senaparib (product code: JS109/IMP4297), had finished its pre-specified interim analysis. Senaparib was jointly developed by Junshi Biosciences and IMPACT Therapeutics, Inc. (“IMPACT Therapeutics”), as a maintenance treatment following first-line platinum-based chemotherapy in patients with International Federation of Gynecology and Obstetrics (“FIGO”) stage III/IV ovarian carcinoma, fallopian tube cancer or primary peritoneal cancer who achieved a complete response or partial response. The Independent Data Monitoring Committee (the “IDMC”) concluded that the primary endpoint had met the pre-defined efficacy boundary. Junshi Biosciences and IMPACT Therapeutics will communicate with regulatory authorities regarding a new drug application for the drug in the near future.

Dr. Jianjun ZOU, President of Global Research and Development at Junshi Biosciences, commented on the positive results of the FLAMES study. “As the first phase III clinical study of a domestically developed PARP inhibitor that has achieved positive results for advanced ovarian cancer maintenance treatment following first-line therapy, the FLAMES study’s interim analysis results show that senaparib can significantly extend the progression free survival (PFS) of patients with advanced ovarian cancer, regardless of the patient’s breast cancer susceptibility gene (BRCA) mutation status. We will collaborate with our partner IMPACT Therapeutics to engage in communication with regulatory agencies and look forward to expanding our commercial cancer drug portfolio to provide more effective treatment options at a lower cost for patients with advanced ovarian cancer.”

Ovarian cancer is one of the most commonly fatal malignant tumors affecting the female genital tract. According to GLOBOCAN 2020 data, around 310,000 new cases of ovarian cancer are diagnosed across the world annually, resulting in roughly 210,000 deaths every year. As the early symptoms of ovarian cancer are hidden and non-specific, around 80% of the patients with ovarian cancer are diagnosed at an advanced stage, with a five-year survival rate of only 40%. Although primary platinum-based chemotherapy can help alleviate ovarian cancer, most patients inevitably experience cancer relapse. Over the years, PARP inhibitor has revolutionized the treatment of ovarian cancer. In particular, PARP inhibitor maintenance treatment can extend the response time following first-line platinum-based chemotherapy and delay cancer relapse.

About the FLAMES Study

The FLAMES Study is a randomized, double-blind, placebo-controlled, multi-center phase III clinical study to evaluate the efficacy and safety of senaparib as monotherapy maintenance treatment following first-line platinum-based chemotherapy in patients with FIGO stage III/IV ovarian cancer who have achieved complete response (CR) or partial response (PR).

About Senaparib

As a novel targeted anti-tumor drug, senaparib is a PARP inhibitor. The clinical study of senaparib was supported by the national special project for innovative manufacturing of major new drugs under the 13th Five-Year Plan, and the inspection and acceptance procedures were completed smoothly. In August 2022, the fixed dose combination capsules of senaparib and temozolomide for the treatment of adult patients with small cell lung cancer was granted orphan-drug designation by the U.S. Food and Drug Administration.

In August 2020, Junshi Biosciences and IMPACT Therapeutics entered into a joint venture agreement to form a joint venture company. The joint venture company mainly engages in the research and development, and commercialization of small molecule anti-tumor drugs, including senaparib. IMPACT Therapeutics contributed the asset rights of senaparib within the joint venture territories of mainland China, Hong Kong and Macau Special Administrative Region. The Company and IMPACT Therapeutics each owns a 50% equity interest of the joint venture company.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8806280

Junshi Biosciences Announces Acceptance of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Operable NSCLC Patients

SHANGHAI, China, April 11, 2023 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, today announced the acceptance of the supplemental new drug application for toripalimab in combination with chemotherapy as perioperative treatment and toripalimab monotherapy as consolidation therapy after adjuvant therapy for the treatment of resectable stage III non-small cell lung cancer (“NSCLC”) by the National Medical Products Administration (“NMPA”).

“This newly applied indication for operable NSCLC patients will open the door to the clinical application of toripalimab in the early stages of the disease,”said Dr. Jianjun ZOU, President of Global Research and Development at Junshi Biosciences. “The Neotorch study has created a new model of perioperative immunotherapy for NSCLC in China, enabling the use of immunotherapy throughout the preoperative, postoperative, and consolidation maintenance processes. We will work closely with regulatory authorities to ensure Chinese patients can benefit from this innovative therapy first and enhance the curative prospects for those with NSCLC.”

Lung cancer is currently the second most prevalent type of cancer with the highest mortality rate in the world. According to data released by the World Health Organization, in 2020, the number of new lung cancer cases in China reached 816,000 and accounted for 17.9% of all new cancer cases in China. In the same year, the number of lung cancer deaths in China reached 715,000 and accounted for 23.8% of all cancer deaths in China. NSCLC is a major subtype of lung cancer, accounting for approximately 85% of all cases. Among these patients, 20%-25% are eligible for surgical resection at first diagnosis, but even after radical surgical treatment, 30%-55% of these patients experience post-surgical recurrence and death. While radical surgery in combination with chemotherapy can prevent recurrence, chemotherapy as preoperative neoadjuvant or postoperative adjuvant therapy has limited clinical benefit, raising the 5-year survival rate of patients by only about 5%.

This supplemental new drug application is based on the Neotorch study (NCT04158440), a randomized, double-blind, placebo-controlled, multi-center phase III clinical study led by Professor Shun LU of Shanghai Chest Hospital as the principal investigator. The study was conducted in 56 centers nationwide. Patients with operable NSCLC received toripalimab/placebo in combination with platinum-containing doublet chemotherapy as neoadjuvant and adjuvant therapy, and received toripalimab/placebo monotherapy as consolidation therapy after postoperative adjuvant therapy. The type of platinum-containing doublet chemotherapy was selected by investigators according to treatment practices of therapeutic institutions—paclitaxel in combination with cisplatin was given to patients with squamous NSCLC, while pemetrexed in combination with cisplatin was given to patients with non-squamous NSCLC.

In January 2023, an interim analysis by the Independent Data Monitoring Committee (IDMC) determined that the primary endpoint of the Neotorch study, event-free survival (“EFS”), had met the pre-defined efficacy boundary. Neotorch is the world’s first phase III registered study demonstrating that perioperative treatment with anti-PD-1 monoclonal antibody significantly extends EFS of patients with operable NSCLC. Results of the interim analysis showed that, compared with chemotherapy alone, toripalimab in combination with chemotherapy as perioperative treatment for stage III operable NSCLC patients and toripalimab monotherapy for consolidation therapy thereafter could significantly extend EFS of patients.

The comprehensive data will be disclosed internationally for the first time in an oral presentation at the ASCO Plenary Series on April 20, 2023, at 3 p.m. (U.S. Eastern time).

About Toripalimab

Toripalimab is an anti-PD-1 monoclonal antibody developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, and for enhanced receptor internalization (endocytosis function). Blocking PD-1 interactions with PD-L1 and PD-L2 promotes the immune system’s ability to attack and kill tumor cells.

More than forty company-sponsored toripalimab clinical studies covering more than fifteen indications have been conducted globally by Junshi Biosciences, including in China, the United States, Southeast Asia, and European countries. Ongoing or completed pivotal clinical trials evaluating the safety and efficacy of toripalimab cover a broad range of tumor types including cancers of the lung, nasopharynx, esophagus, stomach, bladder, breast, liver, kidney and skin.

In China, toripalimab was the first domestic anti-PD-1 monoclonal antibody approved for marketing (approved in China as TUOYI®). Currently, there are six approved indications for toripalimab in China:

  1. unresectable or metastatic melanoma after failure of standard systemic therapy;
  2. recurrent or metastatic NPC after failure of at least two lines of prior systemic therapy;
  3. locally advanced or metastatic urothelial carcinoma that failed platinum-containing chemotherapy or progressed within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy;
  4. in combination with cisplatin and gemcitabine as the first-line treatment for patients with locally recurrent or metastatic NPC;
  5. in combination with paclitaxel and cisplatin in first-line treatment of patients with unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (“ESCC”);
  6. in combination with pemetrexed and platinum as the first-line treatment in EGFR mutation-negative and ALK mutation-negative, unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer (“NSCLC”).

The first three indications have been included in the National Reimbursement Drug List (NRDL) (2022 Edition). Toripalimab is the only anti-PD-1 monoclonal antibody included in the NRDL for treatment of melanoma.

In the United States, the Biologics License Application (BLA) for toripalimab in combination with gemcitabine/cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic NPC and toripalimab monotherapy for the second-line or later treatment of recurrent or metastatic NPC after platinum-containing chemotherapy is under review by the U.S. Food and Drug Administration (FDA). The FDA has granted Breakthrough Therapy designations for toripalimab in combination with chemotherapy for the first-line treatment of recurrent or metastatic NPC as well as for toripalimab monotherapy in the second or third-line treatment of recurrent or metastatic NPC. Additionally, the FDA has granted Fast Track designation for toripalimab for the treatment of mucosal melanoma and Orphan Drug designations for the treatment of esophageal cancer, NPC, mucosal melanoma, soft tissue sarcoma, and small cell lung cancer (SCLC).

In Europe, marketing authorization applications (MAA) were accepted by the European Medicines Agency (EMA) and the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) for 1) toripalimab combined with cisplatin and gemcitabine for the first-line treatment of patients with locally recurrent or metastatic NPC and 2) toripalimab combined with paclitaxel and cisplatin for the first-line treatment of patients with unresectable locally advanced/recurrent or metastatic ESCC, in December 2022 and February 2023.

About Junshi Biosciences

Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutics. The company has established a diversified R&D pipeline comprising over 50 drug candidates, with five therapeutic focus areas covering cancer, autoimmune, metabolic, neurological, and infectious diseases. Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China. Its first-in-human anti-BTLA monoclonal antibody for the treatment of various cancers was the first in the world to be approved for clinical trials by the FDA and NMPA and has since entered Phase Ib/II trials in both China and the US. Its anti-PCSK9 monoclonal antibody was the first in China to be approved for clinical trials by the NMPA.

In the face of the pandemic, Junshi Biosciences’ response was strong and immediate, joining forces with Chinese and international scientific research institutions and enterprises to develop an arsenal of drug candidates to combat COVID-19, taking the initiative to shoulder the social responsibility of Chinese pharmaceutical companies by prioritizing and accelerating COVID-19 R&D. In 2021, JS016 (etesevimab), China’s first neutralizing fully human monoclonal antibody against SARS-CoV-2 administered with bamlanivimab, was granted Emergency Use Authorizations (EUA) in over 15 countries and regions worldwide. Meanwhile, VV116 (deuremidevir hydrobromide), a novel oral nucleoside analog anti-SARS-CoV-2 drug designed to hinder virus replication, has been approved for marketing in China and Uzbekistan. The JS016 and VV116 programs are a part of the company’s continuous efforts towards innovation for disease control and prevention of the global pandemic.

Junshi Biosciences has about 3,000 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc). For more information, please visit: http://junshipharma.com.

Junshi Biosciences Contact Information
IR Team:
Junshi Biosciences
info@junshipharma.com
+ 86 021-6105 8800

PR Team:
Junshi Biosciences
Zhi Li
zhi_li@junshipharma.com
+ 86 021-6105 8800

GlobeNewswire Distribution ID 8806277